These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 17881450)

  • 1. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.
    Lai CJ; Goncalvez AP; Men R; Wernly C; Donau O; Engle RE; Purcell RH
    J Virol; 2007 Dec; 81(23):12766-74. PubMed ID: 17881450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.
    Men R; Yamashiro T; Goncalvez AP; Wernly C; Schofield DJ; Emerson SU; Purcell RH; Lai CJ
    J Virol; 2004 May; 78(9):4665-74. PubMed ID: 15078949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
    Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
    Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.
    Goncalvez AP; Purcell RH; Lai CJ
    J Virol; 2004 Dec; 78(23):12919-28. PubMed ID: 15542644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
    Sukupolvi-Petty S; Austin SK; Engle M; Brien JD; Dowd KA; Williams KL; Johnson S; Rico-Hesse R; Harris E; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2010 Sep; 84(18):9227-39. PubMed ID: 20592088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates.
    Simmons M; Putnak R; Sun P; Burgess T; Marasco WA
    Am J Trop Med Hyg; 2016 Nov; 95(5):1148-1156. PubMed ID: 27645784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
    Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
    BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a humanized antibody with high therapeutic potential against dengue virus type 2.
    Li PC; Liao MY; Cheng PC; Liang JJ; Liu IJ; Chiu CY; Lin YL; Chang GJ; Wu HC
    PLoS Negl Trop Dis; 2012; 6(5):e1636. PubMed ID: 22563515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
    Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
    J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
    PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.
    Goncalvez AP; Men R; Wernly C; Purcell RH; Lai CJ
    J Virol; 2004 Dec; 78(23):12910-8. PubMed ID: 15542643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
    Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1).
    Gelanew T; Poole-Smith BK; Hunsperger E
    J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.
    Moi ML; Ami Y; Shirai K; Lim CK; Suzaki Y; Saito Y; Kitaura K; Saijo M; Suzuki R; Kurane I; Takasaki T
    Am J Trop Med Hyg; 2015 Feb; 92(2):370-6. PubMed ID: 25548383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
    Dowd KA; DeMaso CR; Pierson TC
    mBio; 2015 Nov; 6(6):e01559-15. PubMed ID: 26530385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.